Myeloma bone disease: Pathogenesis, current treatments and future targets

British Medical Bulletin

Volumn 111, Issue 1, 2014, Pages 117-138

  Walker, Rebecca E ^a,b   Lawson, Michelle A ^a,b   Buckle, Clive H ^a,b   Snowden, John A ^a,b   Chantry, Andrew D ^a,b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Bone disease; Myeloma; Therapeutic targets

Indexed keywords

ACTIVIN A; BISPHOSPHONIC ACID DERIVATIVE; BRUTON TYROSINE KINASE INHIBITOR; CELL ADHESION MOLECULE; DENOSUMAB; INTERLEUKIN 3; INTERLEUKIN 6; INTERLEUKIN 7; LENALIDOMIDE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PROTEASOME INHIBITOR; PROTEIN; PROTEIN DICKKOPF; PROTEIN SOSTDC 1; RADIOISOTOPE; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; RECOMBINANT PARATHYROID HORMONE; SCATTER FACTOR; SCLEROSTIN; SECRETED FRIZZLED RELATED PROTEIN; THALIDOMIDE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; WNT INHIBITORY FACTOR 1; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT; CELL AGGREGATION FACTORS; IMMUNOLOGIC FACTOR;

ANTINEOPLASTIC ACTIVITY; BONE DISEASE; BONE MARROW; BONE MARROW MICROENVIRONMENT; CELL ACTIVATION; CLINICAL PRACTICE; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; IMMUNOMODULATION; MYELOMA; MYELOMA BONE DISEASE; NONHUMAN; OSSIFICATION; OSTEOCLAST; OSTEOLYSIS; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN FUNCTION; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SURVIVAL; SYSTEMATIC REVIEW; WNT SIGNALING PATHWAY; BONE DISEASES; COMPLICATION; MULTIPLE MYELOMA; OSTEOBLAST; OSTEOPOROSIS; PHYSIOLOGY;

BONE DENSITY CONSERVATION AGENTS; BONE DISEASES; CELL ADHESION MOLECULES; HUMANS; IMMUNOLOGIC FACTORS; MULTIPLE MYELOMA; OSTEOBLASTS; OSTEOCLASTS; OSTEOPOROSIS;

EID: 84908014150     PISSN: 00071420     EISSN: 14718391     Source Type: Journal    
DOI: 10.1093/bmb/ldu016     Document Type: Review

References (174)

1. Greenlee RT, Murray T, Bolden S, et al. Cancer statistics, 2000. CACancer J Clin 2000;50:7-33.
2. Palumbo A, Rajkumar SV. Treatment of newly diagnosed myeloma. Leukemia 2009;23:449-56.
3. Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 2008;111:2521-6.
4. http://www.cancerresearchuk.org/cancer-info/cancerstats/types/myeloma/survival/multiple-myeloma-survivalstatistics. (6May 2013, date last accessed).
5. Coleman RE. Skeletal complications of malignancy. Cancer 1997;80:1588-94.
6. Kariyawasan CC, Hughes DA, Jayatillake MM, et al. Multiple myeloma: causes and consequences of delay in diagnosis. QJM 2007;100:635-40.
7. Croucher PI, Apperley JF. Bone disease in multiple myeloma. Br J Haematol 1998;103:902-10.
8. Terpos E, Mihou D, Szydlo R, et al. The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/ relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/ osteoprotegerin ratio. Leukemia 2005;19:1969.
9. Menssen HD, Sakalova A, Fontana A, et al. Effects of long-term intravenous ibandronate therapy on skeletalrelated events, survival, and bone resorption markers in patients with advanced multiple myeloma. J Clin Oncol 2002;20:2353-9.
10. Terpos E, Politou M, Rahemtulla A. New insights into the pathophysiology and management of bone disease in multiple myeloma. Br J Haematol 2003;123:758-69.
11. Cocks K, Cohen D, Wisloff F, et al. An international field study of the reliability and validity of a diseasespecific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma. Eur J Cancer 2007;43:1670-8.
12. Vogel CL, Yanagihara RH, Wood AJ, et al. Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy. Oncologist 2004;9:687-95.
13. Boland E, Eiser C, Ezaydi Y, et al. Living with advanced but stable multiple myeloma: a study of the symptom burden and cumulative effects of disease and intensive (hematopoietic stem cell transplant-based) treatment on health-related quality of life. J Pain Symptom Manage 2013;46:671-80.
14. Sonmez M, Akagun T, Topbas M, et al. Effect of pathologic fractures on survival in multiple myeloma patients: a case control study. J Exp Clin Cancer Res 2008;27:11.
15. Basic-kes V, Basic-Jukic N, Kes P, et al. Neurologic sequelae of bone changes in multiple myeloma and its therapy. Acta Med Croatica 2002;56:103-7.
16. Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003;78:21-33.
17. Mundy GR, Raisz LG, Cooper RA, et al. Evidence for the secretion of an osteoclast stimulating factor in myeloma. N Eng J Med 1974;291:1041-6.
18. Terpos E, Dimopoulos MA. Myeloma bone disease: pathophysiology and management. Ann Oncol 2005;16:1223-31.
19. Bataille R, Chappard D, Marcelli C, et al. Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma. J Clin Invest 1991;88:62-6.
20. Calvi LM, Adams GB, Weibrecht KW, et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 2003;425:841-6.
21. Zhang J, Niu C, Ye L, et al. Identification of the haematopoietic stem cell niche and control of the niche size. Nature 2003;425:836-41.
22. Kiel MJ, Yilmaz OH, Iwashita T, et al. SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell 2005;121:1109-21.
23. Noll JE, Williams SA, Purton LE, et al. Tug of war in the haematopoietic stem cell niche: do myeloma plasma cells compete for the HSC niche? Blood Cancer J 2012;2:e91.
24. De Raeve HR, Vanderkerken K. The role of the bone marrow microenvironment in multiple myeloma. Histol Histopathol 2005;20:1227-50.
25. Katz BZ. Adhesion molecules-the lifelines of multiple myeloma cells. Semin Cancer Biol 2010;20:186-95.
26. Sanz-Rodriguez F, Ruiz-Velasco N, Pascual-Salcedo D, et al. Characterization of VLA-4-dependent myeloma cell adhesion to fibronectin and VCAM-1. Br J Haematol 1999;107:825-34.
27. Damiano JS, Cress AE, Hazlehurst LA, et al. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 1999;93:1658-67.
28. Mori Y, Shimizu N, Dallas M, et al. Anti-alpha4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis. Blood 2004;104:2149-54.
29. Jundt F, Probsting KS, Anagnostopoulos I, et al. Jagged1-induced Notch signaling drives proliferation of multiple myeloma cells. Blood 2004;103:3511-5.
30. Houde C, Li Y, Song L, et al. Overexpression of the NOTCH ligand JAG2 in malignant plasma cells from multiple myeloma patients and cell lines. Blood 2004;104:3697-704.
31. Skrtic A, Korac P, Kristo DR, et al. Immunohistochemical analysis of NOTCH1 and JAGGED1 expression in multiple myeloma and monoclonal gammopathy of undetermined significance. Hum Pathol 2010;41: 1702-10.
32. Derycke LD, Bracke ME. N-cadherin in the spotlight of cell-cell adhesion, differentiation, embryogenesis, invasion and signalling. Int J Dev Biol 2004;48:463-76.
33. Groen RW, de Rooij MF, Kocemba KA, et al. N-cadherin-mediated interaction with multiple myeloma cells inhibits osteoblast differentiation. Haematologica 2011;96:1653-61.
34. Vandyke K, Chow AW, Williams SA, et al. Circulating N-cadherin levels are a negative prognostic indicator in patients with multiple myeloma. Br J Haematol 2013;161:499-507.
35. Hay E, Laplantine E, Geoffroy V, et al. N-cadherin interacts with axin and LRP5 to negatively regulate Wnt/beta-catenin signaling, osteoblast function, and bone formation. Mol Cell Biol 2009;29:953-64.
36. Boyce BF, Xing L. Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys 2008;473:139-46.
37. Roux S, Mariette X. The high rate of bone resorption in multiple myeloma is due to RANK (receptor activator of nuclear factor-kappaB) and RANK Ligand expression. Leuk Lymphoma 2004;45:1111-8.
38. Jakob C, Goerke A, Terpos E, et al. Serum levels of total-RANKL in multiple myeloma. Clin Lymphoma Myeloma 2009;9:430-5.
39. Heider U, Langelotz C, Jakob C, et al. Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma. Clin Cancer Res 2003;9:1436-40.
40. Heath DJ, Vanderkerken K, Cheng X, et al. An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma. Cancer Res 2007;67:202-8.
41. Sezer O, Heider U, Jakob C, et al. Human bone marrow myeloma cells express RANKL. J Clin Oncol 2002;20: 353-4.
42. Giuliani N, Bataille R, Mancini C, et al. Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 2001;98:3527-33.
43. Standal T, Seidel C, Hjertner O, et al. Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. Blood 2002;100:3002-7.
44. De Bruyne Eea. Myeloma cells and their interactions with the bone marrow endothelial cells. Curr Immunol Rev 2007;3:41-55.
45. Roodman GD. Treatment strategies for bone disease. Bone Marrow Transplant 2007;40:1139-46.
46. Reddy SV, Takahashi S, Dallas M, et al. Interleukin-6 antisense deoxyoligonucleotides inhibit bone resorption by giant cells from human giant cell tumors of bone. J Bone Miner Res 1994;9:753-7.
47. Urashima M, Ogata A, Chauhan D, et al. Interleukin-6 promotes multiple myeloma cell growth via phosphorylation of retinoblastoma protein. Blood 1996;88:2219-27.
48. Roodman GD. Osteoblast function in myeloma. Bone 2011;48:135-40.
49. Lam J, Takeshita S, Barker JE, et al. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 2000;106:1481-8.
50. Ghali O, Chauveau C, Hardouin P, et al. TNF-alpha's effects on proliferation and apoptosis in human mesenchymal stem cells depend on RUNX2 expression. J Bone Miner Res 2010;25:1616-26.
51. Li B, Shi M, Li J, et al. Elevated tumor necrosis factoralpha suppresses TAZ expression and impairs osteogenic potential of Flk-1+ mesenchymal stem cells in patients with multiple myeloma. Stem Cells Dev 2007;16:921-30.
52. Aggarwal R, Ghobrial IM, Roodman GD. Chemokines in multiple myeloma. Exp Hematol 2006;34:1289-95.
53. Oyajobi BO, Franchin G, Williams PJ, et al. Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease. Blood 2003;102:311-9.
54. Choi SJ, Cruz JC, Craig F, et al. Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood 2000;96:671-5.
55. Terpos E, Politou M, Szydlo R, et al. Serum levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) correlate with the extent of bone disease and survival in patients with multiple myeloma. Br J Haematol 2003;123:106-9.
56. Choi SJ, Oba Y, Gazitt Y, et al. Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease. J Clin Invest 2001;108:1833-41.
57. Dairaghi DJ, Oyajobi BO, Gupta A, et al. CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease. Blood 2012;120:1449-57.
58. Dimopoulos MA, Palumbo A, Attal M, et al. Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement. Leukemia 2011;25:749-60.
59. Derksen PW, de Gorter DJ, Meijer HP, et al. The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma. Leukemia 2003;17:764-74.
60. Grano M, Galimi F, Zambonin G, et al. Hepatocyte growth factor is a coupling factor for osteoclasts and osteoblasts in vitro. Proc Natl Acad Sci U S A 1996;93:7644-8.
61. Borset M, Hjorth-Hansen H, Seidel C, et al. Hepatocyte growth factor and its receptor c-met in multiple myeloma. Blood 1996;88:3998-4004.
62. Seidel C, Borset M, Turesson I, et al. Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. The Nordic Myeloma Study Group. Blood 1998;91:806-12.
63. Standal T, Abildgaard N, Fagerli UM, et al. HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma. Blood 2007;109:3024-30.
64. Lee JW, Chung HY, Ehrlich LA, et al. IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells. Blood 2004;103:2308-15.
65. Ehrlich LA, Roodman GD. The role of immune cells and inflammatory cytokines in Paget's disease and multiple myeloma. Immunol Rev 2005;208:252-66.
66. Silbermann R, Bolzoni M, Storti P, et al. Bone marrow monocyte-/macrophage-derived activin A mediates the osteoclastogenic effect of IL-3 in multiple myeloma. Leukemia 2014;28: 951-54.
67. Abildgaard N, Glerup H, Rungby J, et al. Biochemical markers of bone metabolism reflect osteoclastic and osteoblastic activity in multiple myeloma. Eur J Haematol 2000;64:121-9.
68. Wodarz A, Nusse R. Mechanisms of Wnt signaling in development. Annu Rev Cell Dev Biol 1998;14:59-88.
69. Willert K, Brown JD, Danenberg E, et al. Wnt proteins are lipid-modified and can act as stem cell growth factors. Nature 2003;423:448-52.
70. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature 2005;434:843-50.
71. Westendorf JJ, Kahler RA, Schroeder TM. Wnt signaling in osteoblasts and bone diseases. Gene 2004;341:19-39.
72. Krupnik VE, Sharp JD, Jiang C, et al. Functional and structural diversity of the human Dickkopf gene family. Gene 1999;238:301-13.
73. Mao B, Wu W, Davidson G, et al. Kremen proteins are Dickkopf receptors that regulate Wnt/beta-catenin signalling. Nature 2002;417:664-7.
74. Monroe DG, McGee-Lawrence ME, Oursler MJ, et al. Update on Wnt signaling in bone cell biology and bone disease. Gene 2012;492:1-18.
75. Boyden LM, Mao J, Belsky J, et al. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 2002;346:1513-21.
76. Tian E, Zhan F, Walker R, et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003;349:2483-94.
77. Glass DA 2nd, Bialek P, Ahn JD, et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 2005;8:751-64.
78. Atkins GJ, Kostakis P, Pan B, et al. RANKL expression is related to the differentiation state of human osteoblasts. J Bone Miner Res 2003;18:1088-98.
79. Politou MC, Heath DJ, Rahemtulla A, et al. Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation. Int J Cancer 2006;119:1728-31.
80. Kaiser M, Mieth M, Liebisch P, et al. Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma. Eur J Haematol 2008;80:490-4.
81. Yaccoby S, Ling W, Zhan F, et al. Antibody-based inhibition of DKK1suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood 2007;109:2106-11.
82. Heath DJ, Chantry AD, Buckle CH, et al. Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma. J Bone Miner Res 2009;24:425-36.
83. Fulciniti M, Tassone P, Hideshima T, et al. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 2009;114:371-9.
84. Gunn WG, Conley A, Deininger L, et al. A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma. Stem Cells 2006;24:986-91.
85. Kawano Y, Kypta R. Secreted antagonists of the Wnt signalling pathway. J Cell Sci 2003;116:2627-34.
86. James IE, Kumar S, Barnes MR, et al. FrzB-2: a human secreted frizzled-related protein with a potential role in chondrocyte apoptosis. Osteoarthritis Cartilage 2000;8:452-63.
87. Bodine PV, Billiard J, Moran RA, et al. The Wnt antagonist secreted frizzled-related protein-1 controls osteoblast and osteocyte apoptosis. J Cell Biochem 2005;96:1212-30.
88. Wang FS, Lin CL, Chen YJ, et al. Secreted frizzled-related protein 1 modulates glucocorticoid attenuation of osteogenic activities and bone mass. Endocrinology 2005;146:2415-23.
89. Moore WJ, Kern JC, Bhat R, et al. Modulation of Wnt signaling through inhibition of secreted frizzled-related protein I (sFRP-1) with N-substituted piperidinyl diphenylsulfonyl sulfonamides: part II. Bioorg Med Chem 2010;18:190-201.
90. Nakanishi R, Akiyama H, Kimura H, et al. Osteoblasttargeted expression of Sfrp4 in mice results in low bone mass. J Bone Miner Res 2008;23:271-7.
91. Oshima T, Abe M, Asano J, et al. Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood 2005;106:3160-5.
92. De Vos J, Couderc G, Tarte K, et al. Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays. Blood 2001;98:771-80.
93. Wergedal JE, Veskovic K, Hellan M, et al. Patients with Van Buchem disease, an osteosclerotic genetic disease, have elevated bone formation markers, higher bone density, and greater derived polar moment of inertia than normal. J Clin Endocrinol Metab 2003;88: 5778-83.
94. Mansukhani A, Ambrosetti D, Holmes G, et al. Sox2 induction by FGF and FGFR2 activating mutations inhibits Wnt signaling and osteoblast differentiation. J. Cell Biol. 2005;168:1065-76.
95. ten Dijke P, Krause C, de Gorter DJ, et al. Osteocytederived sclerostin inhibits bone formation: its role in bone morphogenetic protein and Wnt signaling. J Bone Joint Surg Am 2008;90(Suppl 1):31-5.
96. Winkler DG, Sutherland MK, Geoghegan JC, et al. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J 2003;22:6267-76.
97. Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. Lancet 2011;377:1276-87.
98. Terpos E, Christoulas D, Katodritou E, et al. Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: Reduction post-bortezomib monotherapy. Int J Cancer 2013;131:1466-71.
99. Itasaki N, Jones CM, Mercurio S, et al.Wise, a contextdependent activator and inhibitor of Wnt signalling. Development 2003;130:4295-305.
100. Guo X, Wang XF. Signaling cross-talk between TGF-beta/ BMP and other pathways. Cell Res 2009;19:71-88.
101. Geiser AG, Zeng QQ, Sato M, et al. Decreased bone mass and bone elasticity in mice lacking the transforming growth factor-beta1 gene. Bone 1998;23:87-93.
102. Kitisin K, Saha T, Blake T, et al. Tgf-Beta signaling in development. Sci STKE 2007;2007:cm1.
103. Itoh S, Itoh F, Goumans MJ, et al. Signaling of transforming growth factor-beta family members through Smad proteins. Eur J Biochem 2000;267:6954-67.
104. Matsumoto T, Abe M. TGF-beta-related mechanisms of bone destruction in multiple myeloma. Bone 2011;48: 129-34.
105. Mohammad KS, Chen CG, Balooch G, et al. Pharmacologic inhibition of the TGF-beta type I receptor kinase has anabolic and anti-catabolic effects on bone. PLoS One 2009;4:e5275.
106. Vale W, Rivier J, Vaughan J, et al. Purification and characterization of an FSH releasing protein from porcine ovarian follicular fluid. Nature 1986;321:776-9.
107. Ogawa Y, Schmidt DK, Nathan RM, et al. Bovine bone activin enhances bone morphogenetic protein-induced ectopic bone formation. J Biol Chem 1992;267: 14233-37.
108. Eijken M, Swagemakers S, Koedam M, et al. The activin A-follistatin system: potent regulator of human extracellular matrix mineralization. FASEB J 2007;21: 2949-60.
109. Terpos E, Kastritis E, Christoulas D, et al. Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations postlenalidomide and dexamethasone therapy. Ann Oncol 2012;23:2681-6.
110. Chantry AD, Heath D, Mulivor AW, et al. Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo. J Bone Miner Res 2009;25:2633-46.
111. Abdulkadyrov KM, Salogub GN, Khuazheva NK, et al. Sotatercept in patients with osteolytic lesions of multiple myeloma. Brit J Haematol 2014;165: 814-23.
112. Presented in part as an abstract in an oral session at the 51st Annual Meeting of the American Society of Hematology (ASH); New Orleans, LA, USA; December 5-8, 2009.
113. Fuller K, Bayley KE, Chambers TJ. Activin A is an essential cofactor for osteoclast induction. Biochem Biophys Res Commun 2000;268:2-7.
114. Giuliani N, Colla S, Morandi F, et al. Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood 2005;106:2472-83.
115. D'Souza S, Colla S, Morandi F, et al. Gfi1 expressed in bone marrow stromal cells is a novel osteoblast suppressor in patients with multiple myeloma bone disease. Blood 2011;118:6871-80.
116. Snowden JA, del Prete D, Jin S, et al. Guidelines for supportive care in multiple myeloma 2011. Br J Haematol 2011;154:76-103.
117. Schmaus MC, Neuhof D. Radiotherapy for solitary plasmacytoma and multiple myeloma. Radiologe 2014;54:551-5.
118. Hu K, Yahalom J. Radiotherapy in the management of plasma cell tumors. Oncology (Williston Park) 2000;14:101-8, 111; discussion; 111-2. 115.
119. Fleisch H. Development of bisphosphonates. Breast Cancer Res 2002;4:30-4.
120. Belch AR, Bergsagel DE, Wilson K, et al. Effect of daily etidronate on the osteolysis of multiple myeloma. J Clin Oncol 1991;9:1397-402.
121. Lahtinen R, Laakso M, Palva I, et al. Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group. Lancet 1992;340:1049-52.
122. McCloskey EV, MacLennan IC, Drayson MT, et al. A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on leukaemia in adults. Br J Haematol 1998;100: 317-25.
123. Berenson JR, Rosen LS, Howell A, et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 2001;91:1191-200.
124. Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001;7:377-87.
125. Morgan GJ, Davies FE, Gregory WM, et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 2010;376:1989-99.
126. Barri YM, Munshi NC, Sukumalchantra S, et al. Podocyte injury associated glomerulopathies induced by pamidronate. Kidney Int 2004;65:634-41.
127. Berenson JR, Lichtenstein A, Porter L, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol 1998;16:593-602.
128. Chang JT, Green L, Beitz J. Renal failure with the use of zoledronic acid. N Engl J Med 2003;349:1676-9. discussion 1676-1679.
129. Gedmintas L, Solomon DH, Kim SC. Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis. J Bone Miner Res 2013;28:1729-37.
130. Pradhan P, Saxena V, Yadav A, et al. Atypical metatarsal fracture in a patient on long term bisphosphonate therapy. Indian J Orthop 2012;46:589-92.
131. Musto P, Falcone A, Sanpaolo G, et al. Pamidronate reduces skeletal events but does not improve progressionfree survival in early-stage untreated myeloma: results of a randomized trial. Leuk Lymphoma 2003;44:1545-8.
132. Musto P, Petrucci MT, Bringhen S, et al. A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma. Cancer 2008;113:1588-95.
133. Croucher PI, DeHendrik R, Parry MJ, et al. Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreases osteolysis, tumour burden and angiogenesis, and increased survival. J. Bone Miner. Res. 2003;18: 482-92.
134. Lawson MA, Coulton L, Ebetino FH, et al. Geranylgeranyl transferase type II inhibition prevents myeloma bone disease. Biochem Biophys Res Commun 2008; 377:453-7.
135. Sing CE, Alexander-Katz A. Giant nonmonotonic stretching response of a self-associating polymer in shear flow. Phys Rev Lett 2011;107:198302.
136. Mundy GR, Yoneda T. Facilitation and suppression of bone metastasis. Clin Orthop Relat Res 1995;34-44.
137. van der Pluijm G, Vloedgraven H, van Beek E, et al. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest 1996;98:698-705.
138. Shipman CM, Croucher PI, Russell RG, et al. The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res 1998;58:5294-7.
139. Kunzmann V, Bauer E, Feurle J, et al. Stimulation of gamma delta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 2000;96:384-92.
140. Neville-Webbe HL, Rostami-Hodjegan A, Evans CA, et al. Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells. Int J Cancer 2005; 113:364-71.
141. Neville-Webbe HL, Evans CA, Coleman RE, et al. Mechanisms of the synergistic interaction between the bisphosphonate zoledronic acid and the chemotherapy agent paclitaxel in breast cancer cells in vitro. Tumour Biol 2006;27:92-103.
142. Vogt U, Bielawski KP, Bosse U, et al. Breast tumour growth inhibition in vitro through the combination of cyclophosphamide/metotrexate/5-fluorouracil, epirubicin/ cyclophosphamide, epirubicin/paclitaxel, and epirubicin/ docetaxel with the bisphosphonates ibandronate and zoledronic acid. Oncol Rep 2004;12:1109-14.
143. Ottewell PD, Monkkonen H, Jones M, et al. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J. Natl. Cancer Inst. 2008;100:1167-78.
144. Ottewell PD, Woodward JK, Lefley DV, et al. Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone. Mol Cancer Ther 2009;8:2821-32.
145. Rajkumar SV. Zoledronic acid in myeloma: MRC Myeloma IX. Lancet 2010;376:1965-6.
146. Body JJ, Facon T, Coleman RE, et al. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 2006;12:1221-8.
147. Body JJ, Greipp P, Coleman RE, et al. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 2003;97:887-92.
148. Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011;29:1125-32.
149. Burger JA, Buggy JJ. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765). Leuk Lymphoma 2013;54: 2385-91.
150. Tai YT, Chang BY, Kong SY, et al. Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. Blood 2012;120:1877-87.
151. Edwards CM. BTK inhibition in myeloma: targeting the seed and the soil. Blood 2012;120:1757-9.
152. Giammarile F. Bone metastases treated with radiopharmaceuticals. Bull Cancer 2013;100:1223-7.
153. Autio KA, Pandit-Taskar N, Carrasquillo JA, et al. Repetitively dosed docetaxel and (1)(5)(3)samarium- EDTMP as an antitumor strategy for metastatic castration-resistant prostate cancer. Cancer 2013;119: 3186-94.
154. Abruzzese E, Iuliano F, Trawinska MM, et al. 153Sm: its use in multiple myeloma and report of a clinical experience. Expert Opin Investig Drugs 2008;17: 1379-87.
155. Boivin G, Doublier A, Farlay D. Strontium ranelate-a promising therapeutic principle in osteoporosis. J Trace Elem Med Biol 2012;26:153-6.
156. Hodsman AB, Bauer DC, Dempster DW, et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 2005;26:688-703.
157. Pennisi A, Ling W, Li X, et al. Consequences of daily administered parathyroid hormone on myeloma growth, bone disease, and molecular profiling of whole myelomatous bone. PLoS One 2010;5:e15233.
158. Lowik CW, van der Pluijm G, Bloys H, et al. Parathyroid hormone (PTH) and PTH-like protein (PLP) stimulate interleukin-6 production by osteogenic cells: a possible role of interleukin-6 in osteoclastogenesis. Biochem Biophys Res Commun 1989;162:1546-52.
159. Forslund TKA, Koistinen A, Sikiö A. Malignant myeloma in a patient after treatment for osteoporosis with teriparatide; a rare coincidence. Clin Med Case Rep 2008;1:119-22.
160. Harousseau JL, Palumbo A, Richardson PG, et al. Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone. Blood 2010;116: 3743-50.
161. Dimopoulos MA, Richardson PG, Schlag R, et al. VMP (bortezomib, melphalan, and prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study. J Clin Oncol 2009;27:6086-93.
162. Jagannath S, Richardson PG, Barlogie B, et al. Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica 2006;91:929-34.
163. Zangari M, Esseltine D, Lee C-K, et al. Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. Br J Haematol 2005; 131:71-3.
164. Terpos E, Heath DJ, Rahemtulla A, et al. Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. Br JHaematol 2006;135:688-92.
165. Qiang YW, Hu B, Chen Y, et al. Bortezomib induces osteoblast differentiation via Wnt-independent activation of beta-catenin/TCF signaling. Blood 2009;113: 4319-30.
166. Hurchla MA, Garcia-Gomez A, Hornick MC, et al. The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects. Leukemia 2013;27:430-40.
167. Hu B, Chen Y, Usmani SZ, et al. Characterization of the molecular mechanism of the bone-anabolic activity of carfilzomib in multiple myeloma. PLoS One 2013;8: e74191.
168. Bolomsky A, Schreder M, Meissner T, et al. Immunomodulatory drugs thalidomide and lenalidomide affect osteoblast differentiation of human bone marrow stromal cells in vitro. Exp Hematol 2014; 42:516-25.
169. Anderson G, Gries M, Kurihara N, et al. Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1. Blood 2006;107:3098-105.
170. Terpos E, Mihou D, Szydlo R, et al. The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/ relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/ osteoprotegerin ratio. Leukemia 2005;19:1969-76.
171. Breitkreutz IV, Vallet S, Raab MS, et al. Lenalidomide and bortezomib inhibit osteoclast differentiation and activation in multiple myeloma: clinical implications. Blood 2006;108:993a-4a.
172. Morgan GI, Davies FE, Gregory WM, et al. The addition of thalidomide to the induction treatment of newly presenting myeloma patients increases the CR rate which is likely to translate into improved PFS and OS. Blood (ASH AnnualMeeting Abstracts) 2009;114:352.
173. Morgan GJ, Davies FE, Gregory WM, et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 2010;376: 1989-99.
174. Libby E, Garcia D, Quintana D, et al. Disease-specific survival for patients with multiple myeloma: significant improvements over time in all age groups. Leuk Lymphoma 2014.